BioRestorative Therapies Financials
| BRTX Stock | USD 1.50 0.03 1.96% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.78 | 4.3686 |
|
|
Investors should never underestimate BioRestorative Therapies' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BioRestorative Therapies' cash flow, debt, and profitability to make informed and accurate decisions about investing in BioRestorative Therapies.
Net Income |
|
BioRestorative | Select Account or Indicator |
Understanding current and past BioRestorative Therapies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioRestorative Therapies' financial statements are interrelated, with each one affecting the others. For example, an increase in BioRestorative Therapies' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in BioRestorative Therapies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioRestorative Therapies. Check BioRestorative Therapies' Beneish M Score to see the likelihood of BioRestorative Therapies' management manipulating its earnings.
BioRestorative Therapies Stock Summary
BioRestorative Therapies competes with Pulmatrix, Capricor Therapeutics, Akari Therapeutics, Soleno Therapeutics, and Cadrenal Therapeutics,. BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. Biorestorative Therapies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0906556065 |
| CUSIP | 090655606 090655408 85857G109 090655101 090655309 |
| Location | New York; U.S.A |
| Business Address | 40 Marcus Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.biorestorative.com |
| Phone | 631 760 8100 |
| Currency | USD - US Dollar |
BioRestorative Therapies Key Financial Ratios
| Return On Equity | -0.17 | ||||
| Operating Margin | (9.79) % | ||||
| Price To Sales | 28.08 X | ||||
| Revenue | 145.8 K | ||||
| Gross Profit | 119.8 K |
BioRestorative Therapies Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.5M | 4.3M | 22.5M | 16.4M | 12.6M | 13.2M | |
| Other Current Liab | 4.5M | 609.2K | 15.9K | 5.5M | 2.3M | 1.7M | |
| Accounts Payable | 2.0M | 118.9K | 50.8K | 170.9K | 189.4K | 179.9K | |
| Other Current Assets | 35.2K | 105.4K | 436.2K | 363.1K | 305.2K | 320.5K | |
| Total Liab | 14.2M | 5.7M | 856.5K | 602.6K | 2.6M | 2.5M | |
| Intangible Assets | 739.2K | 664.3K | 589.7K | 803.4K | 713.7K | 971.2K | |
| Common Stock | 7.8K | 286.2K | 353.0 | 369.0 | 471.0 | 447.45 | |
| Net Debt | 7.8M | 1.7M | (20.4M) | (1.4M) | (722.1K) | (686.0K) | |
| Retained Earnings | (78.6M) | (89.8M) | (134.1M) | (152.6M) | (146.7M) | (139.4M) | |
| Cash | 1.7K | 3.1M | 21.0M | 1.7M | 884.4K | 840.2K | |
| Long Term Debt | 194.3K | 523.9K | 4.3M | 191.0K | 219.7K | 208.7K | |
| Total Current Assets | 68.9K | 3.2M | 21.5M | 15.1M | 11.4M | 12.0M | |
| Short Term Debt | 7.2M | 316.7K | 297.1K | 278.7K | 162.3K | 154.2K | |
| Net Tangible Assets | (13.5M) | (2.0M) | 21.0M | 15.0M | 17.3M | 18.1M | |
| Short Long Term Debt | 3.5M | 3.6M | 7.1M | 59.0K | 53.1K | 50.4K | |
| Net Receivables | 32K | 17K | 5K | 16K | 19.3K | 22.7K | |
| Net Invested Capital | (5.6M) | 2.9M | 21.8M | 15.8M | 10.0M | 5.9M | |
| Net Working Capital | (13.7M) | 2.1M | 21.1M | 14.7M | 8.8M | 9.2M | |
| Capital Stock | 7.8K | 286.2K | 15.8K | 15.6K | 17.9K | 17.0K |
BioRestorative Therapies Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 5.1M | 1.6M | 1.8M | 11.7K | 13.4K | 12.7K | |
| Operating Income | (8.4M) | (2.8M) | (26.3M) | (19.0M) | (15.2M) | (14.5M) | |
| Ebit | (9.5M) | (9.6M) | (26.4M) | (19.0M) | (15.2M) | (14.5M) | |
| Research Development | 1.7M | 876.8K | 729.1K | 3.5M | 4.0M | 4.2M | |
| Ebitda | (9.3M) | (9.5M) | (26.2M) | (18.9M) | (15.1M) | (14.3M) | |
| Income Before Tax | (14.6M) | (11.3M) | (44.3M) | (18.5M) | (10.4M) | (10.9M) | |
| Net Income | (14.6M) | (12.3M) | (29.9M) | (18.0M) | (10.4M) | (10.9M) | |
| Total Revenue | 130K | 77K | 46K | 119.8K | 145.8K | 120.6K | |
| Net Interest Income | (5.1M) | (1.6M) | (1.8M) | 11.7K | 292.2K | 306.8K |
BioRestorative Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioRestorative Therapies's current stock value. Our valuation model uses many indicators to compare BioRestorative Therapies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioRestorative Therapies competition to find correlations between indicators driving BioRestorative Therapies's intrinsic value. More Info.BioRestorative Therapies is rated second in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, BioRestorative Therapies' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioRestorative Therapies' earnings, one of the primary drivers of an investment's value.BioRestorative Therapies Systematic Risk
BioRestorative Therapies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioRestorative Therapies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on BioRestorative Therapies correlated with the market. If Beta is less than 0 BioRestorative Therapies generally moves in the opposite direction as compared to the market. If BioRestorative Therapies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioRestorative Therapies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioRestorative Therapies is generally in the same direction as the market. If Beta > 1 BioRestorative Therapies moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in BioRestorative Therapies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioRestorative Therapies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BioRestorative Therapies growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
BioRestorative Therapies December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioRestorative Therapies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioRestorative Therapies. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioRestorative Therapies based on widely used predictive technical indicators. In general, we focus on analyzing BioRestorative Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioRestorative Therapies's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 24.86 | |||
| Value At Risk | (6.21) | |||
| Potential Upside | 6.45 |
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.